CannaPharmaRX, Inc. filings document an OTC-traded cannabis operating company with common stock quoted on OTC Markets. The company’s disclosures include Form 8-K reports on material events, corporate updates, board changes, regulatory-status matters and exhibits related to debt payment schedules with significant debtholders.
The filing record also documents the revocation of a British Columbia Securities Commission failure-to-file cease trade order, prior delinquent continuous-disclosure filings, financial-condition risks and going-concern considerations. These filings frame CPMD’s capital structure, governance events, debt obligations and public-company reporting status alongside its cannabis cultivation and export business.
CannaPharmaRX, Inc. notified the SEC that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 under Rule 12b-25 and intends to file the Form 10-Q within five calendar days of the prescribed due date. The notice cites delays in obtaining and compiling required information.
The filing discloses revenues of $627,462 for the three months ended March 31, 2026 versus $335,319 in 2025, and gross losses of $409,453 and $502,607, respectively; the company attributes revenue growth to expansion of its medical cannabis product line and new retail partners.
CannaPharmaRx, Inc. is a Canada-based cannabis cultivator focused on premium dried flower, operating a 55,000 square foot indoor facility in Cremona, Alberta. The company targets medical markets in Canada, Germany, Israel and other EU countries and seeks EU-GMP certification to export directly into Europe.
For the year ended December 31, 2025, CannaPharmaRx generated approximately $1.4 million in revenue but reported a net loss of $11,131,448, an accumulated deficit of $112.3 million, cash of $1,804, and a working capital deficit of $30,278,570. Operating cash flow was negative $789,102, and management states there is substantial doubt about the company’s ability to continue as a going concern without new financing.
The company fully impaired a $4,518,127 investment in LTB Management, concluding expected cash flows were negative. All outstanding convertible notes were past maturity, triggering penalty provisions that produced an accrued penalty liability of $735,002. Its main operating subsidiary is in default under a royalty and security agreement with Koze Investments, which has agreed to forbear enforcing its security over the subsidiary’s equity until May 31, 2026.
At June 30, 2025, the aggregate market value of non‑affiliate equity was $2,583,755. As of March 31, 2026, there were 678,501,405 common shares outstanding, traded on the OTC expert market under the symbol CPMD, with the company highlighting thin liquidity, penny share status, significant dilution risk and heavy regulatory and competitive pressures in the cannabis sector.
CannaPharmaRX, Inc. reported that director Rick Orman resigned from its Board of Directors effective immediately on January 8, 2026. The company states that his resignation did not result from any dispute or disagreement with the company or the Board regarding operations, policies, or practices.
The company also noted that on January 12, 2026, it issued a press release providing corporate updates and outlining its 2026 growth strategy, which has been furnished as an exhibit to this report.
CannaPharmaRX, Inc. reports that the BC Securities Commission has revoked its failure-to-file cease trade order, effective December 12, 2025, after the company completed its previously delinquent Canadian and U.S. filings. The order had stemmed from missing annual financial statements and related disclosures for the year ended December 31, 2022.
Despite this regulatory step, the company highlights substantial doubt about its ability to continue as a going concern. It reports a working capital deficiency of $27,009,769 and related party debt of $10,762,898 with accrued interest of $3,248,127 as of September 30, 2025. Management’s plan includes negotiating debt restructurings, seeking additional working capital, ramping cannabis production at its Cremona, Alberta facility beyond the current six of ten operating grow rooms, and expanding into European markets such as Germany and Israel, supported by a planned EU-GMP certification application.
CannaPharmaRx (CPMD) filed its Q3 2025 report, showing rising sales but continued losses and severe liquidity strain. Revenue reached $656,606 in the quarter (up from $312,164), yet the company posted a gross loss of $440,000 and a net loss of $1,477,811. For the nine months, revenue was $1,223,533 with a net loss of $3,581,863. Cash was $927, total liabilities were $34,133,650, and shareholders’ deficit was $22,516,743. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
On August 7, 2025, the company formalized repayment plans with Koze and affiliates and with Mr. Tal: as of June 30, 2025, about $10 million was owed to Koze and about $0.7 million to Mr. Tal, with interest revised to 6% per annum and 60% of all future profits and capital raised allocated toward repayment. The company is also in default under a royalty/security agreement tied to cannabis sales; Koze agreed to forbear until December 31, 2025. Operations rely on a Formosa lease, with unpaid lease amounts accumulating and a related promissory note now at 6%. Shares outstanding were 662,501,405 as of November 14, 2025.
CannaPharmaRX, Inc. entered into letter agreements that set out payment schedules to address outstanding amounts owed to two significant debtholders. The company states that these schedules are intended to manage existing debt, avoid additional defaults, and still retain capital to grow operations and deliver product. The agreements and their terms had already been described in the company’s quarterly report for the period ended June 30, 2025, but the actual schedule documents were mistakenly omitted. This report is being used to file those repayment schedule agreements as exhibits so they are formally included in the public record.